Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Moodys
McKesson
Boehringer Ingelheim
Colorcon

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Asunaprevir

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Asunaprevir?

Asunaprevir is an investigational drug.

There have been 38 clinical trials for Asunaprevir. The most recent clinical trial was a Phase 3 trial, which was initiated on December 1st 2015.

The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Bristol-Myers Squibb, French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS), and Kirby Institute.

There are twenty-nine US patents protecting this investigational drug and three hundred and eighteen international patents.

Recent Clinical Trials for Asunaprevir
TitleSponsorPhase
Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvirKirby InstitutePhase 4
Triple or Quadruple Combination DAAs Treatment for Subjects With HCV GT 1b InfectionHumanity & Health Medical Group LimitedPhase 2
Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAVKaohsiung Medical University Chung-Ho Memorial HospitalPhase 3

See all Asunaprevir clinical trials

Clinical Trial Summary for Asunaprevir

Top disease conditions for Asunaprevir
Top clinical trial sponsors for Asunaprevir

See all Asunaprevir clinical trials

US Patents for Asunaprevir

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Asunaprevir   Start Trial Method for treating HCV AbbVie Inc. (North Chicago, IL)   Start Trial
Asunaprevir   Start Trial Hepatitis C virus inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Asunaprevir   Start Trial Hepatitis C virus inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Asunaprevir   Start Trial Hepatitis C virus inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Asunaprevir   Start Trial Hepatitis C virus inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Asunaprevir   Start Trial Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-is- oquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolina- mide Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
Asunaprevir   Start Trial Hepatitis C virus inhibitors Bristol-Myers Squibb Company (Princeton, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Asunaprevir

Drugname Country Document Number Estimated Expiration Related US Patent
Asunaprevir Australia 2014239563 2033-03-14   Start Trial
Asunaprevir Australia 2015240754 2033-03-14   Start Trial
Asunaprevir Australia 2016202823 2033-03-14   Start Trial
Asunaprevir Australia 2016291154 2033-03-14   Start Trial
Asunaprevir Australia 2017248487 2033-03-14   Start Trial
Asunaprevir Australia 2018201011 2033-03-14   Start Trial
Asunaprevir Brazil 102018002956 2033-03-14   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
Dow
Express Scripts
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.